Sugi Predict

Sugi Predict / Compounds / SCHEMBL7181268

SCHEMBL7181268

SCHEMBL7181268

Cc1cc(C)c(PC(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c(C)c1.[LiH]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ CYP1A2 P05177 3/20 0.39
▸ CYP3A4 P08684 3/20 0.39
▸ CYP2C19 P33261 3/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.36
▸ ALOX12 P18054 2/20 0.36
▸ TP53 P04637 1/20 0.36
▸ KCNK3 O14649 1/20 0.34
▸ KCNK9 Q9NPC2 1/20 0.34
▸ NOTUM Q6P988 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ RAPGEF4 Q8WZA2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182364 0.89 NOTUM (0.36) LMNAMEN1KMT2AALDH1A1ALOX12
SCHEMBL7174618 0.89 ACHE (0.37) CYP1A2CYP3A4CYP2C19CYP2D6MEN1
SCHEMBL7175826 0.83 ALDH1A1 (0.39) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL7187603 0.81 L3MBTL1 (0.34) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL7186814 0.80 SMN1; SMN2 (0.37) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
Lithium SCHEMBL7175834 0.80 ALDH1A1 (0.39) SMN1; SMN2LMNAHTTCYP1A2CYP3A4
SCHEMBL7184683 0.79 MEN1 (0.39) LMNAHTTCYP1A2CYP3A4CYP2C19
SCHEMBL7174757 0.78 ALDH1A1 (0.41) LMNAHTTMEN1TSHRKMT2A
SCHEMBL7175063 0.78 KMT2A (0.35) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL7176993 0.78 GAA (0.37) LMNAMEN1KMT2AALDH1A1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 SMN1; SMN2 2939/4885LMNA 3241/4885HTT 2802/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 SMN1; SMN2 3105/4885LMNA 3247/4885HTT 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.